Basal and flow-mediated nitric oxide production by atheromatous coronary arteries
D Tousoulis,
C Tentolouris,
T Crake,
P Toutouzas,
and
G Davies
Cardiology Unit, Hippokration Hospital, Athens University Medical School, Greece.
OBJECTIVES: This study assessed the effects of inhibition of nitric oxide synthesis on epicardial human coronary arteries and on coronary flow velocity during baseline conditions and during atrial pacing. BACKGROUND: Epicardial coronary artery dilation occurs in response to an increase in heart rate. It is not known whether the dilation of both angiographically normal and diseased epicardial coronary arteries during atrial pacing is nitric oxide dependent in humans. METHODS: The effects of an intracoronary infusion (4 mumol/min for 8 min) of NG-monomethyl-L-arginine (LNMMA), an inhibitor of nitric oxide synthesis, was studied in 16 patients with coronary artery disease and in 6 patients with normal coronary arteriograms. In all patients atrial pacing was performed during normal saline and during LNMMA infusion. the lumen diameter of epicardial coronary arteries was assessed by quantitative angiography, and changes in blood flow velocity were measured with a Doppler catheter. RESULTS: During saline infusion a significant increase in the lumen diameter of the proximal (p < 0.05) and distal (p < 0.01) segments of both normal and diseased arteries occurred during atrial pacing. No significant lumen diameter changes occurred in either group when atrial pacing was performed during LNMMA infusion. Stenosis diameter decreased during LNMMA infusion but did not change with atrial pacing either during saline infusion or during LNMMA infusion. The mean percent change in coronary blood flow with atrial pacing was less (p < 0.05) during LNMMA infusion than during saline infusion in both groups. CONCLUSIONS: These findings confirm that epicardial coronary artery dilation induced by pacing is nitric oxide dependent. Nitric oxide production contributes to the vasomotor tone of coronary resistance vessels. Nitric oxide is produced at the site of atheromatous stenosis but is unaffected by pacing.
This article has been cited by other articles:

|
 |

|
 |
 
S. E. S. Miner, A. Al-Hesayen, L. E. Nield, T. Gori, and J. D. Parker
Acetylcholine acutely modifies nitric oxide synthase function in the human coronary circulation
Exp Physiol,
December 1, 2010;
95(12):
1167 - 1176.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Seddon, N. Melikian, R. Dworakowski, H. Shabeeh, B. Jiang, J. Byrne, B. Casadei, P. Chowienczyk, and A. M. Shah
Effects of Neuronal Nitric Oxide Synthase on Human Coronary Artery Diameter and Blood Flow In Vivo
Circulation,
May 26, 2009;
119(20):
2656 - 2662.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. Thanyasiri, D. S. Celermajer, and M. R. Adams
Endothelial dysfunction occurs in peripheral circulation patients with acute and stable coronary artery disease
Am J Physiol Heart Circ Physiol,
August 1, 2005;
289(2):
H513 - H517.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D Tousoulis, C Antoniades, and C Stefanadis
Evaluating endothelial function in humans: a guide to invasive and non-invasive techniques
Heart,
April 1, 2005;
91(4):
553 - 558.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. J Green, A. Maiorana, G. O'Driscoll, and R. Taylor
Effect of exercise training on endothelium-derived nitric oxide function in humans
J. Physiol.,
November 15, 2004;
561(1):
1 - 25.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. A. Kaufmann, O. Rimoldi, T. Gnecchi-Ruscone, R. S. Bonser, T. F. Luscher, and P. G. Camici
Systemic Inhibition of Nitric Oxide Synthase Unmasks Neural Constraint of Maximal Myocardial Blood Flow in Humans
Circulation,
September 14, 2004;
110(11):
1431 - 1436.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D Tousoulis, G J Davies, C Tentolouris, T Crake, G Goumas, C Stefanadis, and P Toutouzas
Effects of L-arginine on flow mediated dilatation induced by atrial pacing in diseased epicardial coronary arteries
Heart,
May 1, 2003;
89(5):
531 - 534.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. Tousoulis, C. Antoniades, C. Tentolouris, G. Goumas, C. Stefanadis, and P. Toutouzas
L-Arginine in cardiovascular disease: dream or reality?
Vascular Medicine,
August 1, 2002;
7(3):
203 - 211.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
D Tousoulis, G J Davies, T Crake, and P C Toutouzas
Vasomotion and nitric oxide bioactivity in diseased coronary arteries
Heart,
April 1, 2002;
87(4):
320 - 321.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. J. Mullen, R. K. Kharbanda, J. Cross, A. E. Donald, M. Taylor, P. Vallance, J. E. Deanfield, and R. J. MacAllister
Heterogenous Nature of Flow-Mediated Dilatation in Human Conduit Arteries In Vivo : Relevance to Endothelial Dysfunction in Hypercholesterolemia
Circ. Res.,
February 2, 2001;
88(2):
145 - 151.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D Tousoulis, C Tentolouris, T Crake, G Goumas, C Stefanadis, P Toutouzas, and G Davies
Complex stenosis morphology and vasomotor responses to inhibition of nitric oxide synthesis
Heart,
November 1, 2000;
84(5):
529 - 534.
[Abstract]
[Full Text]
|
 |
|

|
 |

|
 |
 
S. J. Duffy, S. F. Castle, R. W. Harper, and I. T. Meredith
Contribution of Vasodilator Prostanoids and Nitric Oxide to Resting Flow, Metabolic Vasodilation, and Flow-Mediated Dilation in Human Coronary Circulation
Circulation,
November 9, 1999;
100(19):
1951 - 1957.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. De Paulis, F. Tomai, A. Gaspardone, L. Colagrande, P. Nardi, A. Ghini, F. Versaci, A. P. de Peppo, P. A. Gioffre, and L. Chiariello
CORONARY FLOW RESERVE EARLY AND LATE AFTER MINIMALLY INVASIVE CORONARY ARTERY BYPASS GRAFTING IN PATIENTS WITH TOTALLY OCCLUDED LEFT ANTERIOR DESCENDING CORONARY ARTERY
J. Thorac. Cardiovasc. Surg.,
October 1, 1999;
118(4):
604 - 609.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D Tousoulis, C Tentolouris, T Crake, C Stefanadis, P Toutouzas, and G Davies
Evidence of partially preserved endothelial dilator function in diseased coronary arteries
Heart,
October 1, 1999;
82(4):
471 - 476.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D Tousoulis, C Tentolouris, T Crake, G Katsimaglis, C Stefanadis, P Toutouzas, and G J Davies
Effects of L- and D-arginine on the basal tone of human diseased coronary arteries and their responses to substance P
Heart,
May 1, 1999;
81(5):
505 - 511.
[Abstract]
[Full Text]
|
 |
|

|
 |

|
 |
 
A. Prasad, S. Husain, and A. A. Quyyumi
Abnormal flow-mediated epicardial vasomotion in human coronary arteries is improved by angiotensin-converting enzyme inhibition: A potential role of bradykinin
J. Am. Coll. Cardiol.,
March 1, 1999;
33(3):
796 - 804.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. W. Sayer, C. Gutteridge, D. Syndercombe-Court, P. Wilkinson, and A. D. Timmis
Circadian activity of the endogenous fibrinolytic system in stable coronary artery disease: effects of beta-adrenoreceptor blockers and angiotensin-converting enzyme inhibitors
J. Am. Coll. Cardiol.,
December 1, 1998;
32(7):
1962 - 1968.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|